MRNA vs MU

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 19, 2026

MRNA

52.9
AI Score
VS
MU Wins

MU

53.2
AI Score

Investment Advisor Scores

MRNA

53score
Recommendation
HOLD

MU

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA MU Winner
Revenue 534.00M 78.96B MU
Net Income -2.13B 47.27B MU
Net Margin -397.9% 59.9% MU
Operating Income -2.20B 55.59B MU
ROE -31.4% 46.9% MU
ROA -19.4% 35.2% MU
Total Assets 10.96B 134.11B MU
Cash 1.72B 25.00B MU
Current Ratio 2.29 3.42 MU
Free Cash Flow -1.25B 26.10B MU

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% MU 1M: +8.8% · 3M: +9.7%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

MU

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 59

RSI (14): 59.3 · Price: $1088.00

Fundamentals Snapshot

Metric MRNA MU
Market Cap — —
Forward P/E -41.0 5.3
Trailing P/E — 14.1
Revenue (TTM) — —
Revenue Growth 0.0% 3.8%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.8%
EPS -7.36 74.33
Dividend Yield — 0.00%

Frequently Asked Questions

Based on our detailed analysis, MU is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.